Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction

Jasper W. L. Hartog; Ruud M. van de Wal; Casper G. Schalkwijk; Toshio Miyata; Wybren Jaarsma; H. W. Thijs Plokker; Leen M. van Wijk; Andries J. Smit; Dirk J. van Veldhuisen; Adriaan A. Voors

doi:10.1093/eurjhf/hfq001

Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction

Jasper W. L. Hartog^*, Ruud M. van de Wal, Casper G. Schalkwijk, Toshio Miyata, Wybren Jaarsma, H. W. Thijs Plokker, Leen M. van Wijk, Andries J. Smit, Dirk J. van Veldhuisen, Adriaan A. Voors

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

Abstract

Aims To investigate the relationship between advanced glycation end-products (AGEs) and diastolic function and the response to blood pressure treatment in patients with hypertension and diastolic dysfunction.

Methods and results Data were analysed from 97 patients (aged 65 +/- 10 years, 36% male) who were randomly assigned to 6 months open-label treatment with either eprosartan on top of other anti-hypertensive drugs (n = 47) or other antihypertensive drugs alone (n = 50). Tissue AGE accumulation was measured using a validated skin-autofluorescence (skin-AF) reader (n = 26). Plasma N(epsilon)-(carboxymethyl) lysine (CML), N(epsilon)-(carboxyethyl) lysine (CEL), and pentosidine were measured by LC-MS/MS and HPLC. Diastolic function was assessed using echocardiography. Blood pressure was reduced from 157/91 to 145/84 mmHg (P median, E/A ratio (P = 0.84) and mean E' (P = 0.32) remained unchanged.

Conclusion Although eprosartan did not decrease levels of AGEs, patients with lower skin-AF at baseline showed a larger improvement in diastolic function in response to either anti-hypertensive treatment compared with patients with higher skin-AF.

Original language	English
Pages (from-to)	397-403
Number of pages	7
Journal	European Journal of Heart Failure
Volume	12
Issue number	4
DOIs	https://doi.org/10.1093/eurjhf/hfq001
Publication status	Published - Apr-2010

Keywords

Hypertension
Advanced glycation end-products
Diastolic function
Skin-autofluorescence
Tissue velocity imaging
VASCULAR SMOOTH-MUSCLE
CHRONIC HEART-FAILURE
SKIN-AUTOFLUORESCENCE
VENTRICULAR PROPERTIES
PROGNOSTIC VALUE
ACCUMULATION
PENTOSIDINE
MECHANISMS
IRBESARTAN
VALSARTAN

Access to Document

10.1093/eurjhf/hfq001

Cite this

Hartog, J. W. L., van de Wal, R. M., Schalkwijk, C. G., Miyata, T., Jaarsma, W., Plokker, H. W. T., van Wijk, L. M., Smit, A. J., van Veldhuisen, D. J., & Voors, A. A. (2010). Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. European Journal of Heart Failure, 12(4), 397-403. https://doi.org/10.1093/eurjhf/hfq001

Hartog, Jasper W. L. ; van de Wal, Ruud M. ; Schalkwijk, Casper G. ; Miyata, Toshio ; Jaarsma, Wybren ; Plokker, H. W. Thijs ; van Wijk, Leen M. ; Smit, Andries J. ; van Veldhuisen, Dirk J. ; Voors, Adriaan A. / Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. In: European Journal of Heart Failure. 2010 ; Vol. 12, No. 4. pp. 397-403.

@article{4f77f3bfa50342fab3aaf1938abdf1cc,

title = "Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction",

abstract = "Aims To investigate the relationship between advanced glycation end-products (AGEs) and diastolic function and the response to blood pressure treatment in patients with hypertension and diastolic dysfunction.Methods and results Data were analysed from 97 patients (aged 65 +/- 10 years, 36% male) who were randomly assigned to 6 months open-label treatment with either eprosartan on top of other anti-hypertensive drugs (n = 47) or other antihypertensive drugs alone (n = 50). Tissue AGE accumulation was measured using a validated skin-autofluorescence (skin-AF) reader (n = 26). Plasma N(epsilon)-(carboxymethyl) lysine (CML), N(epsilon)-(carboxyethyl) lysine (CEL), and pentosidine were measured by LC-MS/MS and HPLC. Diastolic function was assessed using echocardiography. Blood pressure was reduced from 157/91 to 145/84 mmHg (P median, E/A ratio (P = 0.84) and mean E' (P = 0.32) remained unchanged.Conclusion Although eprosartan did not decrease levels of AGEs, patients with lower skin-AF at baseline showed a larger improvement in diastolic function in response to either anti-hypertensive treatment compared with patients with higher skin-AF.",

keywords = "Hypertension, Advanced glycation end-products, Diastolic function, Skin-autofluorescence, Tissue velocity imaging, VASCULAR SMOOTH-MUSCLE, CHRONIC HEART-FAILURE, SKIN-AUTOFLUORESCENCE, VENTRICULAR PROPERTIES, PROGNOSTIC VALUE, ACCUMULATION, PENTOSIDINE, MECHANISMS, IRBESARTAN, VALSARTAN",

author = "Hartog, {Jasper W. L.} and {van de Wal}, {Ruud M.} and Schalkwijk, {Casper G.} and Toshio Miyata and Wybren Jaarsma and Plokker, {H. W. Thijs} and {van Wijk}, {Leen M.} and Smit, {Andries J.} and {van Veldhuisen}, {Dirk J.} and Voors, {Adriaan A.}",

year = "2010",

month = apr,

doi = "10.1093/eurjhf/hfq001",

language = "English",

volume = "12",

pages = "397--403",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley",

number = "4",

}

Hartog, JWL, van de Wal, RM, Schalkwijk, CG, Miyata, T, Jaarsma, W, Plokker, HWT, van Wijk, LM, Smit, AJ , van Veldhuisen, DJ & Voors, AA 2010, 'Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction', European Journal of Heart Failure, vol. 12, no. 4, pp. 397-403. https://doi.org/10.1093/eurjhf/hfq001

Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. / Hartog, Jasper W. L.; van de Wal, Ruud M.; Schalkwijk, Casper G.; Miyata, Toshio; Jaarsma, Wybren; Plokker, H. W. Thijs; van Wijk, Leen M.; Smit, Andries J.; van Veldhuisen, Dirk J.; Voors, Adriaan A.

In: European Journal of Heart Failure, Vol. 12, No. 4, 04.2010, p. 397-403.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction

AU - Hartog, Jasper W. L.

AU - van de Wal, Ruud M.

AU - Schalkwijk, Casper G.

AU - Miyata, Toshio

AU - Jaarsma, Wybren

AU - Plokker, H. W. Thijs

AU - van Wijk, Leen M.

AU - Smit, Andries J.

AU - van Veldhuisen, Dirk J.

AU - Voors, Adriaan A.

PY - 2010/4

Y1 - 2010/4

N2 - Aims To investigate the relationship between advanced glycation end-products (AGEs) and diastolic function and the response to blood pressure treatment in patients with hypertension and diastolic dysfunction.Methods and results Data were analysed from 97 patients (aged 65 +/- 10 years, 36% male) who were randomly assigned to 6 months open-label treatment with either eprosartan on top of other anti-hypertensive drugs (n = 47) or other antihypertensive drugs alone (n = 50). Tissue AGE accumulation was measured using a validated skin-autofluorescence (skin-AF) reader (n = 26). Plasma N(epsilon)-(carboxymethyl) lysine (CML), N(epsilon)-(carboxyethyl) lysine (CEL), and pentosidine were measured by LC-MS/MS and HPLC. Diastolic function was assessed using echocardiography. Blood pressure was reduced from 157/91 to 145/84 mmHg (P median, E/A ratio (P = 0.84) and mean E' (P = 0.32) remained unchanged.Conclusion Although eprosartan did not decrease levels of AGEs, patients with lower skin-AF at baseline showed a larger improvement in diastolic function in response to either anti-hypertensive treatment compared with patients with higher skin-AF.

AB - Aims To investigate the relationship between advanced glycation end-products (AGEs) and diastolic function and the response to blood pressure treatment in patients with hypertension and diastolic dysfunction.Methods and results Data were analysed from 97 patients (aged 65 +/- 10 years, 36% male) who were randomly assigned to 6 months open-label treatment with either eprosartan on top of other anti-hypertensive drugs (n = 47) or other antihypertensive drugs alone (n = 50). Tissue AGE accumulation was measured using a validated skin-autofluorescence (skin-AF) reader (n = 26). Plasma N(epsilon)-(carboxymethyl) lysine (CML), N(epsilon)-(carboxyethyl) lysine (CEL), and pentosidine were measured by LC-MS/MS and HPLC. Diastolic function was assessed using echocardiography. Blood pressure was reduced from 157/91 to 145/84 mmHg (P median, E/A ratio (P = 0.84) and mean E' (P = 0.32) remained unchanged.Conclusion Although eprosartan did not decrease levels of AGEs, patients with lower skin-AF at baseline showed a larger improvement in diastolic function in response to either anti-hypertensive treatment compared with patients with higher skin-AF.

KW - Hypertension

KW - Advanced glycation end-products

KW - Diastolic function

KW - Skin-autofluorescence

KW - Tissue velocity imaging

KW - VASCULAR SMOOTH-MUSCLE

KW - CHRONIC HEART-FAILURE

KW - SKIN-AUTOFLUORESCENCE

KW - VENTRICULAR PROPERTIES

KW - PROGNOSTIC VALUE

KW - ACCUMULATION

KW - PENTOSIDINE

KW - MECHANISMS

KW - IRBESARTAN

KW - VALSARTAN

U2 - 10.1093/eurjhf/hfq001

DO - 10.1093/eurjhf/hfq001

M3 - Article

VL - 12

SP - 397

EP - 403

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 4

ER -